Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
4.180
-0.050 (-1.18%)
At close: Mar 6, 2026, 4:00 PM EST
4.990
+0.810 (19.38%)
After-hours: Mar 6, 2026, 7:59 PM EST
Lisata Therapeutics Employees
Lisata Therapeutics had 26 employees as of December 31, 2024. The number of employees increased by 1 or 4.00% compared to the previous year.
Employees
26
Change (1Y)
1
Growth (1Y)
4.00%
Revenue / Employee
$41,154
Profits / Employee
-$701,615
Market Cap
36.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Xilio Therapeutics | 64 |
| Atara Biotherapeutics | 38 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| INmune Bio | 22 |
| CervoMed | 15 |
LSTA News
- 21 hours ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 5 weeks ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - GlobeNewsWire
- 4 months ago - Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 4 months ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 4 months ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire